V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008858 | 330011951 | 1.75 | 46.2 | Palliative (P) | 2013-03-31 | 2013-04-08 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 330022355 | BORTEZOMIB |
| 330008859 | 330005654 | null | 56 | Palliative (P) | 2018-10-23 | 2018-10-23 | Bevacizumab 15mg/kg | 2 | N | 330022399 | PEMBROLIZUMAB |
| 330008860 | 330005655 | 1.87 | 35.9 | Palliative (P) | 2017-05-20 | 2017-05-20 | BEP 5 Day | 02 | N | 330022399 | CISPLATIN + GEMCITABINE |
| 330008861 | 330005655 | 1.82 | 14 | Palliative (P) | 2017-09-04 | 2017-10-13 | VIDE | null | N | 330022399 | CETUXIMAB + CISPLATIN + FU |
| 330008862 | 330005655 | 1.72 | 67.4 | Palliative (P) | 2017-05-03 | 2017-05-03 | Epirubicin | N | null | 330022399 | IPO |
| 330008863 | 330005656 | null | 71.799 | Curative (C) | 2016-02-13 | 2016-02-20 | Cyclophosphamide High Dose | 2 | N | 330022445 | AFATINIB |
| 330008864 | 330005657 | 1.84 | 73.9 | Disease modification (D) | 2016-08-21 | 2016-08-22 | POMB | 02 | N | 330022445 | VIDE |
| 330008865 | 330009089 | null | 140.8 | Adjuvant (A) | 2017-04-25 | 2017-05-20 | TRASTUZUMAB | N | N | 330022462 | CVP R |
| 330008866 | 330005659 | 1.7 | 56 | Palliative (P) | 2014-11-15 | 2014-11-16 | PONATINIB | 02 | N | 330022463 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008867 | 330005660 | 1.83 | 72 | Palliative (P) | 2013-04-06 | 2013-05-02 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | 330022484 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330008868 | 330005661 | 1.73 | 71 | Curative (C) | 2017-09-16 | 2017-09-16 | LIPOSOMAL DAUNORUBICIN | 2 | N | 330022491 | TRIPLE INTRATHECAL |
| 330008869 | 330005662 | null | 78 | Curative (C) | 2016-11-30 | 2016-12-14 | Cladribine (subcut) 5 days | N | N | 330022493 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE |
| 330008870 | 330009091 | 1.8 | 73 | Curative (C) | 2015-12-30 | 2016-01-13 | CYCLOPHOSPHAMIDE + VINORELBINE | N | N | 330022493 | LIPOSOMAL DAUNORUBICIN |
| 330008871 | 330005663 | 1.54 | 60.5 | Curative (C) | 2014-03-24 | 2014-07-25 | EMA/CO | N | null | 330022530 | MITOTANE |
| 330008872 | 330005665 | 1.67 | 57.7 | Palliative (P) | 2014-08-17 | 2014-08-27 | CHLORAMBUCIL + RITUXIMAB | N | N | 330022533 | EMA/CO |
| 330008873 | 330005666 | 0 | 77 | Palliative (P) | 2014-12-03 | 2014-12-08 | EDP + MITOTANE | N | N | 330022589 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330008874 | 330009094 | null | 110 | Disease modification (D) | 2016-11-25 | 2016-11-25 | EMA/CO | 02 | N | 330022594 | DOXORUBICIN + HD MTX |
| 330008875 | 330009094 | null | 91.8 | Curative (C) | null | 2013-09-12 | AML17 TRIAL | N | N | 330022594 | IBRUTINIB |
| 330008876 | 330005668 | 1.77 | 64 | Disease modification (D) | 2013-09-19 | 2013-10-27 | UKALL14- Ph 1 Induction | 2 | N | 330022662 | UKALL60+ |
| 330008877 | 330005670 | 1.8 | 56.4 | Palliative (P) | 2017-06-27 | 2017-06-27 | IBRUTINIB | N | N | 330022662 | VIDE |
| 330008878 | 330005672 | null | 60 | Palliative (P) | 2017-10-23 | 2017-11-11 | BEP 5 Day | 02 | N | 330022740 | DOXORUBICIN + OLARATUMAB |
| 330008879 | 330005673 | null | 9.5 | Palliative (P) | 2017-12-22 | 2017-12-22 | Dactinomycin + Vincristine | N | N | 330022760 | DACTINOMYCIN |
| 330008880 | 330005674 | 1.75 | 73.5 | Neo-adjuvant (N) | 2015-10-05 | 2015-10-05 | LIPOSOMAL DAUNORUBICIN | 02 | N | 330022788 | IFOSFAMIDE |
| 330008883 | 330005675 | 1.59 | 65.4 | Adjuvant (A) | 2018-01-27 | 2018-01-31 | Hydroxycarbamide | 02 | N | 330022807 | CVD (NEUROENDOCRINE) |
| 330008884 | 330005678 | 1.06 | 65.5 | Curative (C) | 2015-07-02 | 2015-07-05 | CAPECITABINE + CARBOPLATIN + Cetuximab | 02 | N | 330022818 | AML17 TRIAL |
| 330008885 | 330009099 | null | 69.6 | Palliative (P) | 2015-10-08 | 2015-10-28 | Hydroxycarbamide | 02 | N | 330022818 | CARBOPLATIN + CETUXIMAB + FU |
| 330008886 | 330005679 | null | 60.8 | Palliative (P) | 2014-06-24 | 2014-07-13 | IPO | N | N | 330022832 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330008887 | 330005681 | 1.62 | 59.4 | Curative (C) | 2017-11-02 | 2017-11-07 | CHLORAMBUCIL + RITUXIMAB | N | N | 330022876 | CVD (NEUROENDOCRINE) |
| 330008888 | 330005682 | 1.73 | 56.7 | null | 2017-01-25 | 2017-02-28 | Dactinomycin + Vincristine | null | Y | 330022880 | UKALL2014 |
| 330008889 | 330005684 | 1.6 | null | Neo-adjuvant (N) | 2016-03-10 | 2016-06-16 | DHAP | N | N | 330022893 | PERTUZUMAB + TRASTUZUMAB |
| 330008890 | 330010942 | 1.62 | 84.5 | Palliative (P) | 2017-06-25 | 2017-06-25 | MA (Cytarabine 3g/m2) | 2 | N | 330022900 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008892 | 330009102 | 1.86 | 80 | Curative (C) | 2014-09-08 | 2014-09-21 | AML17 TRIAL | 02 | N | 330022920 | EC |
| 330008893 | 330009102 | 1.63 | null | Disease modification (D) | 2014-10-13 | 2014-11-27 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | N | 330022920 | PCV |
| 330008894 | 330009102 | null | 8.4 | null | 2016-04-16 | 2016-04-16 | UKALL14- Ph 2 Induction | N | N | 330022920 | VIDE |
| 330008895 | 330005690 | 1.67 | 93 | Palliative (P) | 2013-12-17 | 2013-12-27 | Doxorubicin + Gemcitabine | N | N | 330022926 | CLADRIBINE |
| 330008896 | 330005690 | 1.82 | 48.6 | Palliative (P) | 2017-05-25 | 2017-06-23 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | null | N | 330022926 | BORTEZOMIB |
| 330008897 | 330013193 | 1.7 | 0 | Palliative (P) | 2017-02-19 | 2017-02-19 | DHAP - R | N | null | 330022938 | CAPECITABINE + CISPLATIN |
| 330008898 | 330005691 | null | 69.1 | Palliative (P) | 2017-09-09 | 2017-10-12 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | null | 330022958 | CISPLATIN + GEMCITABINE |
| 330008899 | 330012542 | 0 | 23.6 | Curative (C) | 2017-09-08 | 2017-09-08 | CNS LGG Irinotecan & Bevacizumab | N | null | 330022970 | VINCRISTINE |
| 330008901 | 330005696 | 1.8 | 83 | Palliative (P) | 2018-06-20 | 2018-06-21 | Capecitabine + Streptozocin | N | N | 330022979 | VINCRISTINE |
| 330008902 | 330005696 | 1.71 | 77.9 | Palliative (P) | 2016-07-07 | 2016-07-07 | ALL UKALL2011 Ind A Sht Dex (PAsp) | 02 | N | 330022979 | CISPLATIN + GEMCITABINE |
| 330008904 | 330005699 | null | 55.8 | Curative (C) | 2014-01-26 | 2014-06-25 | VIDE | N | N | 330023013 | CHLORAMBUCIL |
| 330008905 | 330005700 | 1.73 | 56.21 | Curative (C) | 2017-05-16 | 2017-05-16 | Erlotinib | 01 | N | 330023014 | IVA |
| 330008906 | 330005701 | null | 68.35 | null | 2019-01-22 | 2019-01-22 | Hydroxycarbamide | 02 | N | 330023021 | IFOSFAMIDE |
| 330008907 | 330005705 | 1.74 | 74 | Curative (C) | 2015-01-01 | 2015-02-12 | Capecitabine + Cisplatin | N | N | 330023042 | TRIPLE INTRATHECAL |
| 330008908 | 330009111 | 1.98 | null | null | 2013-03-03 | 2013-03-22 | Cyclophosphamide High Dose | Y | N | 330023042 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330008909 | 330005706 | 1.79 | 84.4 | Curative (C) | 2017-03-13 | 2017-03-24 | PEI | N | N | 330023058 | AFATINIB |
| 330008910 | 330009112 | 1.15 | 12.3 | Curative (C) | null | 2014-02-25 | Alemtuzumab + Cyclophos TBI Allo | null | null | 330023058 | CISPLATIN + FLUOROURACIL + RT |
| 330008915 | 330005707 | 1.72 | null | Curative (C) | 2016-08-08 | 2016-09-12 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | N | N | 330023087 | CAPECITABINE + CISPLATIN |
| 330008916 | 330005708 | 1.84 | 80 | Curative (C) | 2013-05-09 | 2013-05-16 | BEP 5 Day | N | N | 330023091 | MABCUTE TRIAL |